May 25, 2017 8:00am EDT Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting NY-ESO in Combination with KEYTRUDA® (pembrolizumab) in Multiple Myeloma
May 16, 2017 7:59am EDT Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors
May 10, 2017 7:30am EDT Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting AFP in Liver Cancer
May 02, 2017 11:00am EDT Adaptimmune to Present at Upcoming Deutsche Bank 42nd Annual Health Care Conference
Apr 10, 2017 1:32pm EDT Adaptimmune Therapeutics plc Announces Closing of $42 Million Registered Direct Offering
Apr 05, 2017 8:33am EDT Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares
Mar 27, 2017 11:26am EDT Adaptimmune Therapeutics plc Announces Closing of Public Offering and Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares